Everything below concerns Quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
Quality control for NMN materials usually covers identity, assay purity, residual solvents, heavy metals, microbial limits, and moisture content. Certificates of analysis from suppliers may report high-performance liquid chromatography purity, mass spectrometry identity, and elemental impurity testing. Regulatory treatment differs by country: NMN is not an approved drug, and its status as a dietary supplement ingredient or novel food has been debated. Some authorities have restricted sales pending safety and regulatory review, while others allow it under specific categories. Buyers should verify documentation rather than rely on label claims.
Quantifying NMN requires methods that separate it from structurally similar compounds such as nicotinamide, nicotinamide riboside, and NAD+. Common approaches include high-performance liquid chromatography coupled with ultraviolet detection, liquid chromatography with tandem mass spectrometry, capillary electrophoresis, and nuclear magnetic resonance for identity confirmation. Because NMN is polar and often present at low concentrations in biological samples, sample preparation can involve protein precipitation, solid-phase extraction, or derivatization. Isotope-labeled internal standards help correct for matrix effects and recovery losses. Reported concentrations depend heavily on the matrix, extraction protocol, and analytical platform.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
==== Employee training ==== All employees whose jobs in health care facilities expose them to hazardous drugs must receive training. Training should include shipping and receiving personnel, housekeepers, pharmacists, assistants, and all individuals involved in the transportation and storage of antineoplastic drugs. These individuals should receive information and training to inform them of the hazards of the drugs present in their areas of work. They should be informed and trained on operations and procedures in their work areas where they can encounter hazards, different methods used to detect the presence of hazardous drugs and how the hazards are released, and the physical and health hazards of the drugs, including their reproductive and carcinogenic hazard potential. Additionally, they should be informed and trained on the measures they should take to avoid and protect themselves from these hazards. This information ought to be provided when health care workers come into contact with the drugs, that is, perform the initial assignment in a work area with hazardous drugs. Moreover, training should also be provided when new hazards emerge as well as when new drugs, procedures, or equipment are introduced.
(2017) in a Kozak-like region in the SOX9 gene that created a new translation initiation codon in an out-of-frame open reading frame. The correct initiation codon was located in a region that did not match the Kozak consensus sequence as closely as the surrounding sequence of the new, upstream initiation site did, which resulted in reduced translation efficiency of functional SOX9 protein. The patient in whom this mutation was detected had developed acampomelic campomelic dysplasia, a developmental disorder that causes skeletal, reproductive and airway issues due to insufficient SOX9 expression.
Distortion of the corneal optics. This begins usually when the pterygium is greater than 2mm from the corneal limbus. Disruption of the tear. The tear film is the first lens in the eye. Pterygia are associated with eyelid inflammation, called blepharitis. Growth over the corneal centre, which leads to dramatic reduction of vision. Induced anterior corneal scarring, which often remains after surgical removal. A pterygium of the eye grows very slowly. Usually it takes several years or decades to progress.
== Symptoms == In the case of the autosomal dominant form of the disease, kittens are often born with abnormally soft and velvety skin. Normal scratching and playing with other cats will begin to cause tears in the skin, usually starting at around eight weeks of age. Injuries often heal rapidly, leaving scars. Rarely, joint overmobility can result from the disease. Autosomal recessive cats can develop extreme skin hyperextensibility, but do not suffer from joint hypermobility.
=== 2014–present: Return to acting and resurgence === Larter returned to the big screen playing Molly Kingston, the love interest of Charlie Darby, a successful but psychotic man (Matt LeBlanc) in the comedy Lovesick (2014). The film screened at the 15th annual Newport Beach Film Festival in Newport Beach, California and was released for VOD and selected theaters. She portrayed Keely, the "fair-weather" friend of Kate Parker (Hilary Swank), a woman with ALS in the independent drama You're Not You (2014), directed by George C. Wolfe. Her co-stars were Emmy Rossum and Josh Duhamel. In 2014, Larter obtained a regular part in the first season of TNT's drama series Legends, appearing as Crystal McGuire, an operative with the FBI's Deep Cover Operations. She starred in the supernatural thriller The Diabolical as Madison, a single mother who battles evil forces in her house. Released in 2015 at South by Southwest in Austin, Texas, it was distributed for a VOD and limited release in only certain parts of the United States. The film received largely mixed reviews; Gary Goldstein of the Los Angeles Times felt that her "fraught, more seemingly complex [character] remains underdeveloped" in what he described as a "weak horror-thriller". Larter starred in Resident Evil: The Final Chapter (2016), where her role of Claire teams up with Alice (Jovovich) and the Red Queen (Ever Anderson) to save the remnants of humanity. Despite a largely mixed critical response it grossed over $312 million worldwide. The film is Larter's biggest box office success.
Sources: en.wikipedia.org
== History == Tom Kudirka, originally from Omaha, Nebraska, and an alumnus of Bellevue West High School, had studied business information systems and electronics before moving to Tulsa to work for Lucent Technologies as a field engineer. Thereafter, he had established multimedia companies, including one dealing with speech recognition. Because Kudirka "thought he was bored", he founded 2015 in Tulsa in May 1997. The name was said to have been chosen for an undisclosed "very significant" reason, although Kudirka later said he did not know what it meant. Kudirka recruited developers he had discovered online and had them relocate to Tulsa. The designer Zied Rieke was the first hire. Through Kudirka's connections with Ritual Entertainment and its CEO, 2015 came to develop Wages of Sin, an expansion pack for Ritual Entertainment's 1998 game Sin. It was released in February 1999. On April 3, 2000, 2015 announced the opening of its Trainwreck Studios division for budget-price games with a wider target audience. The first game therein, Laser Arena, was designed to be playable by Kudirka's three-year-old son and released in September 2000. 2015 was simultaneously working on its third game, Heavy Gear Extreme. The company grew to 15 people, requiring it to expand its office space at 8282 South Memorial Drive. The second Trainwreck Studios game, CIA Operative: Solo Missions, was released in May 2001. 2015 was reported as developing Half-Life: Hostile Takeover as an expansion for Half-Life in November 1999.
=== Predators === Newborn rattlesnakes are heavily preyed upon by a variety of species, including cats, ravens, crows, roadrunners, raccoons, opossums, skunks, coyotes, weasels, whipsnakes, kingsnakes, and racers. Young of the smaller crotaline species are frequently killed and eaten by small predatory birds, such as jays, kingfishers, and shrikes. Some species of ants in the genus Formica are known to prey upon neonates, and Solenopsis invicta (fire ants) likely do, as well. On occasion, hungry adult rattlesnakes cannibalize neonates. The small proportion (often as few as 20%) of rattlesnakes that make it to their second year are heavily preyed upon by a variety of larger predators, including coyotes, eagles, hawks, owls, falcons, feral pigs, badgers, indigo snakes, and kingsnakes. The common kingsnake (Lampropeltis getula), a constrictor, is immune to the venom of rattlesnakes and other vipers, and rattlesnakes form part of its natural diet. Rattlesnakes sense kingsnakes' presence by their odor. When they realize a kingsnake is nearby, they begin enacting a set of defensive postures known as "body bridging". Unlike its normal erect and coiled defensive-striking posture, the rattlesnake keeps its head low to the ground in an attempt to prevent the kingsnake from gaining a hold on it (the head being the first part of the rattlesnake to be ingested). The rattlesnake jerks its body about, while bridging its back upwards, forming an elevated coil that faces the kingsnake. The elevated coil is used to strike the attacker, and is also used to shield the head from the kingsnake.
== Clinical significance == PAT1 mRNA is expressed in the GI tract between the stomach and descending colon, but is generally absent in the esophagus, caecum, and rectum. This allows for different treatments that affect the affinity of the carrier protein for its substrates, giving the potential to treat various amino-acid related diseases. HPAT1 and HPAT2 are important in the absorption of certain drugs, especially pharmaceutically active amino acids derivatives. They have also been targeted with medications used as anticonvulsants, for prostate cancer, and for bladder cancer. HPAT1 and 2 are integral to the central nervous system because they transport GABA and its analogues which can induce and inhibitory and excitatory effect in the brain.
Eva Smolková-Keulemansová (née Weilová; 27 April 1927 – 27 February 2024) was a Czech scientist and Holocaust survivor. After she survived the Auschwitz, Neuengamme and Bergen-Belsen concentration camps, she became a renowned scientist and professor of analytical science at Charles University in Prague.
Sources: en.wikipedia.org
=== Ayurveda (5th/6th century BC) === Ayurveda is a Hindu system of medicine with historic roots in the Indian subcontinent. Some of its conceptual origins trace back to the Indus Valley civilisation. It developed significantly through the Vedic period. Polyuria in diabetes was associated with a sweet taste of urine in Sanskrit texts of the 5th/6th century BC, at the time of two notable physicians Sushruta and Charaka. They described several diseases of polyuric nature collectively called Prameha ("to flow"). Included in this group of ailments was the equivalent of diabetes mellitus, madhumeha ("honey urine"), named as such because the sweet urine of patients would attract ants and flies. These patients are said to have suffered from extreme thirst and foul breath. Ayurvedic texts provided dietary prescriptions for the condition. They constitute the earliest known references to the presence of sugar in the urine (glycosuria) and to dietary remedies, at least a thousand years before modern European descriptions began to more comprehensively conceptualize the disease. Sushruta and Charaka also identified the two types of diabetes mellitus, later dubbed Type I and Type II diabetes.
=== Economic situation === Because of their wide needs, the overall chelating agents growth was 4% annually during 2009–2014 and the trend is likely to increase. Aminopolycarboxylic acids chelators are the most widely consumed chelating agents; however, the percentage of the greener alternative chelators in this category continues to grow. The consumption of traditional aminopolycarboxylates chelators, in particular the EDTA (ethylenediaminetetraacetic acid) and NTA (nitrilotriacetic acid), is declining (−6% annually), because of the persisting concerns over their toxicity and negative environmental impact. In 2013, these greener alternative chelants represented approximately 15% of the total aminopolycarboxylic acids demand. This is expected to rise to around 21% by 2018, replacing and aminophosphonic acids used in cleaning applications. Examples of some Greener alternative chelating agents include ethylenediamine disuccinic acid (EDDS), polyaspartic acid (PASA), methylglycinediacetic acid (MGDA), glutamic diacetic acid (L-GLDA), citrate, gluconic acid, amino acids, plant extracts etc.
== History == Cold hemagglutination was first reported by Landsteiner in 1903 and found to occur in human beings in 1918. The association of cold hemagglutination with hemolysis was described in 1937 by Rosenthal and Corten. During the 1960s, Dacie and Schubothe published systematic descriptions of 16 CAD patients each. The auto antibodies responsible for hemagglutination at low temperatures, cold agglutinins (CA), may be found in the sera of healthy subjects as well as in patients with AIHA of the cold reactive types. CA bind to erythrocyte surface antigens at a temperature optimum of 0–4 °C. In contrast to polyclonal CA in healthy individuals, monoclonal CA often have a high-thermal amplitude, which contributes to their pathogenicity at temperatures approaching 37 °C. Binding of CA causes agglutination of erythrocytes and the antigen–antibody complex induces complement (C) activation and hemolysis. Essential clinical manifestations of primary CAD are hemolytic anemia and cold-induced circulatory symptoms. Exact estimates of the severity of anemia and the frequency of cold-induced symptoms, however, have not been provided until recent years.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
Liquid chromatography with tandem mass spectrometry is common because it can quantify low levels of NMN in complex samples. High-performance liquid chromatography with ultraviolet detection is used for simpler purity checks. Nuclear magnetic resonance can confirm identity and detect some impurities.